Frontline Treatment Options for LR-MDS Beyond ESAs
Panelists discuss how the NCCN Guidelines define lower-risk myelodysplastic syndrome (LR-MDS) based on clinical hallmarks such as anemia and cytopenias, with treatment decisions guided by prognostic scoring systems (IPSS-R, IPSS-M), and how real-world data supports the evolving first-line treatment landscape for LR-MDS, including the use of therapies such as luspatercept.
- Please provide a brief overview of LR-MDS per NCCN Guidelines.
- Briefly describe clinical hallmarks that lead to an MDS diagnosis.
- What are the available treatments for anemia in patients with LR-MDS?
- With treatment decisions for LR-MDS, how do you incorporate prognostic scoring systems (IPSS-R, IPSS-M) in the first-line decision-making process?
- Please elaborate on how these scoring systems influence the choice between available options.
- Please discuss the real-world data related to first-line treatment options for LR-MDS (Fonseca et al, MDS #276 SOHO 2024; Garcia-Manero et al, Clin Lymph Myel Leuk 2024).
- Please elaborate on how this evidence supports the changing landscape for first-line treatment for lower-risk MDS.
Recent Videos
Related Content
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Article
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
